Kling Bio has announced the appointment of Dr Stefano Gullà as Chief Scientific Officer.
Stefano has over 15 years of experience in biotherapeutics discovery and development.
Prior to joining Kling, he held senior positions at Pfizer, Agenus, Flagship and RVAC where he led the discovery and development of its first-in-class therapeutics with applications in immuno-oncology and autoimmunity.
Stefano enthused: “Kling’s technology is a powerful discovery engine that enables simultaneous and unbiased identification of new targets and therapeutic antibodies.”
He added: “I am excited about the potential to scale this clinically proven platform, focusing on cancer and emerging infectious diseases, and look forward to working with Kling’s exceptionally talented leadership team to continue building value for patients by advancing life-changing medicines into the clinic.”
